Showing
1 - 4
results of
4
for search '
Agashivala, N.
'
Skip to content
Home
Collections
High Impact Articles
Jawi Collection
Malay Medicine
Search Options
UiTM Open Access
Search by UiTM Scopus
Advanced Search
Search by Category
Discovery Service
Sources
UiTM Journals
List UiTM Journal in IR
Statistic
About
Open Access
Creative Commons Licenses
COKI | Malaysia Open Access
Report Technical
User Guide
Contact Us
Search Tips
FAQs
All Fields
Title
Author
Subject
Call Number
ISBN/ISSN
Tag
Find
Advanced
Author
Agashivala, N.
Showing
1 - 4
results of
4
for search '
Agashivala, N.
'
, query time: 0.04s
Refine Results
Sort
Relevance
Date Descending
Date Ascending
Call Number
Author
Title
1
A cross-sectional survey of patient satisfaction and subjective experiences of treatment with fingolimod
by
Hanson KA
,
Agashivala
N
,
Stringer SM
,
Balantac Z
,
Brandes DW
Published 2013-04-01
Get full text
Article
2
Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: A cost-effectiveness analysis
by
Agashivala
,
N
.
,
Carlton, R.
,
Hassan, T.
,
Wykoff, C.C
,
Yu, J.S
Published 2021
Call Number:
Loading...
Located:
Loading...
View Fulltext in Publisher
Article
3
Treatment selection and experience in multiple sclerosis: survey of neurologists
by
Hanson KA
,
Agashivala
N
,
Wyrwich KW
,
Raimundo K
,
Kim E
,
Brandes DW
Published 2014-04-01
Get full text
Article
4
Patient perspectives on switching disease-modifying therapies in the NARCOMS registry
by
Salter AR
,
Marrie RA
,
Agashivala
N
,
Belletti DA
,
Kim E
,
Cutter GR
,
Cofield SS
,
Tyry T
Published 2014-07-01
Get full text
Article
Search Tools:
Get RSS Feed
—
Email this Search
Related Subjects
Adolescent
Adult
Angiogenesis Inhibitors
Antibodies, Monoclonal, Humanized
Article
Cost-Benefit Analysis
Cross-Sectional Studies
Female
Humans
Male
Markov chain
Middle Aged
Ranibizumab
Receptors, Vascular Endothelial Growth Factor
Recombinant Fusion Proteins
Visual Acuity
Wet Macular Degeneration
Young Adult
adolescent
adult
aflibercept
angiogenesis inhibitor
best corrected visual acuity
brolucizumab
cohort analysis
controlled study
cost benefit analysis
cost effectiveness analysis
cross-sectional study
drug cost
Loading...